Physician profile
Davinder Singh
NPI 1194945592
$2,158.46
in general payments reported to CMS, 2019-2025
20 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $462 · 2020: $54.55 · 2021: $208 · 2022: $388 · 2023: $528 · 2024: $398 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,045.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $356.37 | 2021-2023 | |
| Horizon Therapeutics Plc | $315.73 | 2019-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $289.66 | 2019-2024 | Jynarque |
| Novartis Pharmaceuticals Corporation | $231.53 | 2019-2024 | |
| Amgen INC. | $171.14 | 2021-2025 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $160.76 | 2019-2024 | Farxiga |
| Cvrx, INC. | $112.40 | 2024 | Barostim Neo System |
| Aurinia Pharma U.S., INC. | $74.18 | 2021-2023 | Lupkynis |
| Nxstage Medical, INC. | $71.46 | 2019 | |
| Mallinckrodt Hospital Products INC. | $67.60 | 2021-2024 | Acthar |
| Fresenius USA Marketing, INC. | $47.18 | 2019 | |
| Akebia Therapeutics INC | $45.17 | 2019-2025 | Vafseo |
| Vifor Pharma, INC. | $42.51 | 2020-2022 | |
| Alnylam Pharmaceuticals INC. | $40.04 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.93 | 2023-2024 | Jardiance |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $29.46 | 2024 | Jardiance |
| Calliditas Therapeutics US INC. | $18.39 | 2024 | |
| Amicus Therapeutics, INC. | $17.50 | 2024 | Galafold |
| Hikma Pharmaceuticals USA | $17.28 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Davinder Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.